Back

One year after: what are the implications of the new The ESC/EAS LDL-c Guidelines for PCSK9i?

29 August 2020 (18:35 - 18:50)
Organised by:
Congress Presentation Part of: PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities Lipid-Lowering Agents Open Access ESC Congress 2020

About the speaker

Photo
Professor Francois Mach

University hospitals of Geneva, Geneva (Switzerland)

4 More presentations in this session

Presentation thumbnail
Introduction.
Professor J. Kastelein (Amsterdam, NL)
Video
Presentation thumbnail
Five years of PCSK9i: Lessons from practice, which patients do benefit most?
Professor E. Stroes (Amsterdam, NL)
Video
Presentation thumbnail
Time to reduce the implementation gaps-the role of PCSK9i in routine practice
Professor K. Ray (London, GB)
Video
Presentation thumbnail
Discussion.
Professor J. Kastelein (Amsterdam, NL)
Video

Access the full session

Session thumbnail
PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities
Video

The Event

Event poster

ESC Congress 2020

29 August 2020 18:35 CET
You may be interested in
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
New trial evidence in the field of lipid management
thumbnail
Congress Presentation
2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources